MedTech Spectrum

Article Name Clinical Trials and Research

Trinity Biotech Announces Successful Clinical Results for Enhanced EpiCapture Prostate Cancer Test

This next-generation version of EpiCapture utilises machine learning tools that integrate additional patient features, including patient ethnicity

25th March, 2026

Akrivia Biosciences Unveils Breakthrough in Decoding Breast Cancer Genome Complexity

Akrivia is currently preparing to deploy T-OMICS as a targeted decision-support tool specifically designed to address the unmet needs of the advanced breast cancer patient population

25th March, 2026

Amydis Receives Phase 2 NIH Grant Award to Advance a Novel Approach to Detect Biomarker TDP-43

Approximately 97 per cent of people diagnosed with ALS have TDP-43 pathology, making it a central biological hallmark of the disease

13th March, 2026

Philips Advances Connected Care with AI-Enabled Health Platforms

Health systems are under unprecedented pressure, with rapidly growing data volumes stretching clinical capacity and contributing to care delays

11th March, 2026

More Preventive Healthcare Professionals Through Technical Diplomas

Singapore’s healthcare system has long been recognised for its strong infrastructure, advanced medical capabilities, and forward-looking policies. In recent years, however, the focus of healthcare development has expanded beyond treatment and hospital care to include a stronger emphasis on preventive healthcare.

09th March, 2026

SeaStar Medical Completes FDA-Mandated SAVE Registry Enrollment for QUELIMMUNE Therapy

Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements

06th March, 2026

Egle Therapeutics and Consortium Partners Awarded €8 Million Grant from Horizon Europe

This funding from the European Union will support an Egle-led initiative in partnership with a consortium of four leading European scientific institutions to advance the clinical development of EGL-001

02nd March, 2026

FDA’s CDRH Clears SMO India Clinical Research as Authorised Third-Party Evaluator

With this recognition, SMO India becomes one of a select group of organisations globally authorised under the FDA’s Third-Party Review Program

24th February, 2026

P-Cure Announces First-Ever Prospective Clinical Results of Gantry-Less Upright Proton Therapy

The P-Cure centre is the first and only facility in the world to routinely deliver proton therapy to patients using its upright technology

17th February, 2026

EYE PCR Receives CE Mark for fixOflex Endocapsular Device

CE Mark certification enables commercialisation across Europe and other CE-recognising markets

13th February, 2026

Balt’s Squid Liquid Embolic Receives FDA Approval for Adjunctive Treatment for Patients with Chronic Subdural Hematomas

The approval comes following the results from The Squid Trial for the Embolisation of the Middle meningeal artery (STEM) for the treatment of chronic Sub-Dural Hematoma study

06th February, 2026

SMART and NUS Pioneer Neural Blueprint for Human-like Intelligence in Soft Robots

A newly developed AI control system using neuron-inspired learning enables soft robotic arms to learn a broad set of motions once and adapt instantly to changing conditions without retraining

05th February, 2026

Trace Biosciences Announces FDA IND Clearance for First Nerve-Specific Imaging Agent

The IND clearance enables Trace to initiate first-in-human clinical studies evaluating the safety and intraoperative performance of LGW16-03 in surgical settings

02nd February, 2026

Laborie Acquires the JADA System for Rapid Postpartum Haemorrhage Control

The JADA System for treatment of abnormal postpartum uterine bleeding, and the team behind the product, join Laborie, strengthening the company's commitment to improving maternal health

29th January, 2026

Redefining Cardiopulmonary Trials with Functional Imaging Biomarkers

Polarean’s Xenon MRI platform is opening a new window into the pulmonary microvasculature, long considered a “silent zone” in cardiopulmonary disease and reshaping how pharma sponsors evaluate therapeutic response

23rd January, 2026